Profil bibliographique

Tarek M. Mostafa

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

71Publications signalées

1058Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Liver Disease Diagnosis and TreatmentMetabolism, Diabetes, and CancerLiver Disease and TransplantationDrug-Induced Hepatotoxicity and ProtectionBiochemical Acid Research Studies

Publications récentes

2026 articleOpenAlex

Ondansetron versus gabapentin in preventing postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a randomized study

Aya Gamal Moussa, Sahar M El-Haggar, Tamer M. Elmahdy, Tarek M. Mostafa

0 citationsNaunyn-Schmiedeberg s Archives of Pharmacology

Accès ouvert 2026 preprintOpenAlex

L-Carnitine and Biotin as Adjunctive Therapies in Children with Moderate Persistent Asthma: A Randomized Placebo controlled Study

Mohamed O. Khedr, Sahar M. El-Haggar, Ahmed M. Abd El-Razik, Rehab Elmeazawy et autres

0 citationsResearch Square

Accès ouvert 2026 articleOpenAlex

Additional file 1 of Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial

Bassant M. Mahboub, Ayman Refaie, Sahar M. El-Haggar, Yasser Mostafa Hafez et autres

0 citationsFigshare

Accès ouvert 2026 articleOpenAlex

Additional file 1 of Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial

Bassant M. Mahboub, Ayman Refaie, Sahar M. El-Haggar, Yasser Mostafa Hafez et autres

0 citationsFigshare

Accès ouvert 2025 articleOpenAlex

Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial

Bassant M. Mahboub, Ayman Refaie, Sahar M. El-Haggar, Yasser Mostafa Hafez et autres

1 citationDiabetology & Metabolic Syndrome

2025 articleOpenAlex

Comparative clinical study to evaluate the efficacy and safety of roflumilast versus alpha-lipoic acid in type 2 diabetic patients with diabetic neuropathy

Asmaa E.A. Elsharab, Tarek M. Mostafa, Mohamed Zakarya Nooh, Dalia El‐Afify

0 citationsJournal of the Neurological Sciences

Accès ouvert 2025 articleOpenAlex

Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study

Asmaa Elsharab, Mohamed Zakarya Nooh, Raghda Samy Ahmed El-Meligy Matard, Tarek M. Mostafa et autres

1 citationDiabetes Metabolic Syndrome and Obesity

Accès ouvert 2025 reviewOpenAlex

Role of dexmedetomidine in brain injury: a systematic review

Rania Zekry, Rehab H. Werida, Ehab S. Hegazy, Tarek M. Mostafa

1 citationInflammopharmacology

Accès ouvert 2025 articleOpenAlex

Clinical study evaluating the gastroprotective effect of carvedilol in patients with ischemic heart disease on aspirin therapy

Sarah M. Elkablawy, Aliaa E. Shaban, Tarek M. Mostafa

2 citationsInflammopharmacology

Accès ouvert 2025 articleOpenAlex

Efficacy and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with rheumatoid arthritis: a randomized controlled study

Tarek M. Mostafa, Abeer A. Elsayed, Abdel Moaty A. Afifi, Dalia El‐Afify

0 citationsEuropean Journal of Clinical Pharmacology

Accès ouvert 2025 erratumOpenAlex

Correction: Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database

Lena Gajdos, Niccolò Buetti, Alexis Tabah, Stéphane Ruckly et autres

0 citationsIntensive Care Medicine

2025 articleOpenAlex

Pentoxifylline as Adjuvant Therapy in Patients with Generalized Epilepsy Treated with Phenytoin: A Randomized Controlled Study

Maha A. Younis, Sahar M El-Haggar, Wessam Mustafa, Tarek M. Mostafa

2 citationsMolecular Neurobiology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.